Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation De effecten van vernakalant en flecaïnide op de atriale contractiliteit bij patiënten met atriumfibrilleren
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Flecainide (Primary) ; Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- 19 Jul 2012 Planned initiation date 1 Aug 2012, lead trial investigators added and planned number of patients changed from 50 to 70 as reported by ClinicalTrials.gov record.
- 19 Jul 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01646281).
- 19 Jul 2012 Planned End Date changed from 25 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov record.